The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and economic value of three acute treatments for migraine.
In giving the final verdict on what would constitute a fair US price for Eli Lilly’s (NYSE: LLY) Reyvow (lasmiditan), Ubrelvy (ubrogepant) from Allergan (NYSE: AGN) and Biohaven’s (NYSE: BHVN) rimegepant, the ICER has changed its position.
Previously, ICER had estimated a health-benefit price benchmark of $2,200 to $3,200 per year for all three treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze